EUR 0.23
(-1.74%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 31.56 Million EUR | -5.91% |
2022 | 33.55 Million EUR | -14.1% |
2021 | 39.05 Million EUR | -5.73% |
2020 | 41.43 Million EUR | 168.25% |
2019 | 15.44 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 FY | 31.56 Million EUR | -5.91% |
2023 Q4 | 31.56 Million EUR | 0.0% |
2023 Q2 | 36.75 Million EUR | 0.0% |
2023 Q1 | 36.75 Million EUR | 9.55% |
2022 Q4 | 33.55 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
European Medical Solutions | 33.86 Million EUR | 6.789% |
FERMENTALG | 19.39 Million EUR | -62.733% |
argenx SE | 402.79 Million EUR | 92.163% |
BioSenic S.A. | 32.26 Million EUR | 2.16% |
Celyad Oncology SA | 9.97 Million EUR | -216.366% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -266.547% |
Onward Medical N.V. | 25.69 Million EUR | -22.838% |
Oxurion NV | 19.73 Million EUR | -59.946% |
PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -22.853% |
Financière de Tubize SA | 123.65 Million EUR | 74.471% |
UCB SA | 6.56 Billion EUR | 99.519% |